Kimia Biosciences FY26 Performance and Board Restructuring Update

Profit After Tax dropped to Rs 743.37 lakh from Rs 961.24 lakh in FY25. Revenue from operations fell to Rs 11,488.38 lakh from Rs 11,892.08 lakh.
Reader Takeaway: Positive R&D milestone with Luliconazole patent tempered by declining financial margins and rising board leadership changes.

What just happened

Kimia Biosciences has released its financial results for the year ended March 31, 2026, showing a decline across key metrics. The company also announced significant leadership changes, including the resignation of multiple directors and the appointment of new board members and key managerial personnel. Shareholders are now preparing for the 33rd Annual General Meeting scheduled for September 28, 2026.

Why this matters

The financial contraction, highlighted by a reduction in basic EPS to 1.64, draws focus to the company’s cost management. Simultaneously, the proposal to increase borrowing limits and asset charges up to Rs 100 crore indicates the company's intent to leverage its balance sheet despite the current performance pressure.

What changes now

The board composition has been significantly refreshed with new Independent and Non-Executive directors effective April 2026. Further, the appointment of a new CFO and Company Secretary marks a complete transition in key operational management roles.

Risks to watch

Investors should track the ongoing income tax litigation for AY 2019-20 involving a demand of Rs 122.40 lakh. Additionally, the company recorded fines paid to the BSE for listing compliance failures during the year, which investors should monitor as a governance signal.

What to track next

The upcoming AGM will be crucial, as shareholders will vote on the proposed increase in debt-raising authorities and the ratification of cost auditor remuneration. Success in commercializing the recently patented Luliconazole remains a key operational pivot point.